Anders Benteson Nygaard

Anders Benteson Nygaard

Auto-generated profile, based on publicly available information

Anders Benteson Nygaard

Department of Microbiology, Oslo University Hospital, Oslo, Norway

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ANAnders B. Nygaard
Anders B. Nygaard
HTHege S. Tunsjø
Hege S. Tunsjø
RMRoger Meisal
Roger Meisal
CCColin Charnock
Colin Charnock
There is a growing awareness of the importance of indoor microbiomes for human health. Given their complexity, these microbiomes can only be adequately surveyed using high throughput sequencing techniques. Oxford Nanopore’s MinION is the newest third generation sequencing technology on the market. With its many advantages such as portability, user friendliness, simplicity, speed of sequencing and long read length, the technology is now an actual contender to established sequencing platforms. MinION’s main disadvantage is a relatively low read accuracy compared to several other platforms, although this is constantly improving. The present study, which appears to be the first of its kind, provides the results of a preliminary analysis of the microbial communities in indoor environments based on 16S rRNA gene amplicon sequencing, using both the Oxford Nanopore Technologies (ONT) MinIOn and the Illumina MiSeq DNA sequencers. At the level of family and above, there was no significant difference between the microbial compositions as revealed by the two platforms. However, at the genus, and particularly at the species level, the ONT MinION reported greater taxonomic resolution than Illumina MiSeq.

7 September 2022 in BMJ
Verified
Journal Article
Open access
PDF file
SBSonja H Brunvoll
Sonja H Brunvoll
ANAnders B Nygaard
Anders B Nygaard
MEMerete Ellingjord-Dale
Merete Ellingjord-Dale
PHPetter Holland
Petter Holland
MIMette Stausland Istre
Mette Stausland Istre
ASArne Søraas
Arne Søraas
Objective To determine if daily supplementation with cod liver oil, a low dose vitamin D supplement, in winter, prevents SARS-CoV-2 infection, serious covid-19, or other acute respiratory infections in adults in Norway. Design Quadruple blinded, randomised placebo controlled trial. Setting Norway, 10 November 2020 to 2 June 2021. Participants 34 601 adults (aged 18-75 years), not taking daily vitamin D supplements. Intervention 5 mL/day of cod liver oil (10 µg of vitamin D, n=17 278) or placebo (n=17 323) for up to six months. Main outcome measures Four co-primary endpoints were predefined: the first was a positive SARS-CoV-2 test result determined by reverse transcriptase-quantitative polymerase chain reaction and the second was serious covid-19, defined as self-reported dyspnoea, admission to hospital, or death. Other acute respiratory infections were indicated by the third and fourth co-primary endpoints: a negative SARS-CoV-2 test result and self-reported symptoms. Side effects related to the supplementation were self-reported. The fallback method was used to handle multiple comparisons. Results Supplementation with cod liver oil was not associated with a reduced risk of any of the co-primary endpoints. Participants took the supplement (cod liver oil or placebo) for a median of 164 days, and 227 (1.31%) participants in the cod liver oil group and 228 (1.32%) participants in the placebo group had a positive SARS-CoV-2 test result (relative risk 1.00, multiple comparison adjusted confidence interval 0.82 to 1.22). Serious covid-19 was identified in 121 (0.70%) participants in the cod liver oil group and in 101 (0.58%) participants in the placebo group (1.20, 0.87 to 1.65). 8546 (49.46%) and 8565 (49.44%) participants in the cod liver oil and placebo groups, respectively, had ≥1 negative SARS-CoV-2 test results (1.00, 0.97 to 1.04). 3964 (22.94%) and 3834 (22.13%) participants in the cod liver oil and placebo groups, respectively, reported ≥1 acute respiratory infections (1.04, 0.97 to 1.11). Only low grade side effects were reported in the cod liver oil and placebo groups. Conclusion Supplementation with cod liver oil in the winter did not reduce the incidence of SARS-CoV-2 infection, serious covid-19, or other acute respiratory infections compared with placebo. Trial registration ClinicalTrials.gov NCT04609423.

15 September 2018 in Microbiome
Verified
Journal Article
Open access
PDF file
ANAnders B. Nygaard
Anders B. Nygaard
CCColin Charnock
Colin Charnock
In Norway, 91% of children aged 1–5 attend kindergarten where they are exposed to indoor microbiomes which can have relevance for development and health. In order to gain a better understanding of the composition of the indoor microbiome and how it is affected by occupancy over time, floor dust samples from a newly opened kindergarten were investigated. Samples were collected during an 11-month period. Samples were analyzed for bacterial composition using 16S rRNA gene sequencing. Samples were also screened for four clinically relevant antibiotic resistance genes. In addition, Petrifilm analyses were used to evaluate surface hygiene. Significant changes in the microbial community composition were observed over time (PERMANOVA, P < 0.05). Particularly, changes in the abundance and the proportions of human associated bacteria were found. A decrease in the prevalence of Propionibacterium from over 16% abundance to less than 1% and an increase in Streptococcus from 10 to 16% were the most significant findings. Four classes of clinically relevant antibiotic resistance genes were tested for; three were detected in the dust, indicating the presence of resistant bacteria and a potential for resistance spread. Petrifilm analysis showed that some surfaces in the kindergarten were of consistent poor hygienic quality, and new hygienic routines are required. This study, which is the first of its kind performed at a newly opened kindergarten, reveals changes in the microbiome over time as well as the presence of antibiotic resistance genes and hygiene issues which are of relevance for occupant health.

12 November 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
SBSonja H. Brunvoll
Sonja H. Brunvoll
ANAnders B. Nygaard
Anders B. Nygaard
MFMorten W. Fagerland
Morten W. Fagerland
PHPetter Holland
Petter Holland
MEMerete Ellingjord-Dale
Merete Ellingjord-Dale
ASArne Søraas
Arne Søraas
We aimed to describe post-acute sequelae of SARS-CoV-2 infection (PASC) related symptoms 3-15 months after a positive test in SARS-CoV-2 unvaccinated and vaccinated participants with a breakthrough infection. Participants of the Norwegian COVID-19 cohort, without a positive SARS-CoV-2 test, completed a questionnaire about PASC-related symptoms between November 2020 and January 2021. About a year later, a second questionnaire (which also included the Everyday Memory Questionnaire [EMQ]-13) was completed by the same participants, most still without a positive SARS-CoV-2 test, but also by unvaccinated and vaccinated participants with a positive test 3-15 months before the questionnaire. Laboratory-confirmed SARS-CoV-2 status (positive or negative swab test determined by reverse transcriptase quantitative polymerase chain reaction) at the time of completing the questionnaire was ascertained from the Mandatory Norwegian Surveillance System for Communicable Diseases. No differences were found in the self-reported PASC symptoms, dyspnea, fatigue, smell/taste changes, concentration problems, or the EMQ-13 score between unvaccinated and vaccinated participants 3-15 months after the positive test. Fewer memory problems were reported among vaccinated than unvaccinated participants. SARS-CoV-2 vaccines offer minor protection against PASC symptoms, although fewer memory problems were reported among the vaccinated than the unvaccinated participants.

8 September 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
ASArne Søraas
Arne Søraas
GGGunnveig Grødeland
Gunnveig Grødeland
BGBeathe Kiland Granerud
Beathe Kiland Granerud
TUThor Ueland
Thor Ueland
ALAndreas Lind
Andreas Lind
FLFridtjof Lund-Johansen
Fridtjof Lund-Johansen
Background: Results showing that sera from double vaccinated individuals have minimal neutralizing activity against Omicron have been interpreted as indicating the need for a third vaccine dose for protection. However, there is little information about early immune responses to Omicron infection in double vaccinated individuals.Methods: We measured inflammatory mediators, antibodies to the SARS-CoV-2 spike and nucleocapsid proteins, and spike peptide-induced release of interferon gamma in whole blood in 51 double-vaccinated individuals infected with Omicron, in 14 infected with Delta, and in 18 healthy controls. The median time points for the first and second samples were 7 and 14 days after symptom onset, respectively.Findings: Infection with Omicron or Delta led to a rapid and similar increase in antibodies to the receptor-binding domain (RBD) of Omicron protein and spike peptide-induced interferon gamma in whole blood. Both the Omicron- and the Delta-infected patients had a mild and transient increase in inflammatory parameters.Interpretation: The results suggest that two vaccine doses are sufficient to mount a rapid and potent immune response upon infection in healthy individuals of with the Omicron variant.Funding: The study was funded by the Oslo University Hospital, and by grants from The Coalition for Epidemic Preparedness Innovations, Research Council of Norway (no 312780, 324272), South-Eastern Norway Regional Health Authority (no 2019067, 2021071, 10357, 2021047, 33612, 2021087, 2017092), EU Horizon 2020 grant no 848099, a philantropic donation from Vivaldi Invest A/S, and The European Virus Archive Global.

9 June 2017 in Indoor and Built Environment
Verified
Journal Article
Closed access
ANAnders B Nygaard
Anders B Nygaard
CCColin Charnock
Colin Charnock
The microbial content of dust collected from intake and exhaust air filters in six Norwegian nurseries was determined using 16S rRNA pyrosequencing and plate count analyses. The concentration of endotoxins was also estimated. About 96% of the sequences were classified as Actinobacteria, Proteobacteria, Firmicutes, Bacteroidetes and Cyanobacteria. At the genus level, about 30% of sequences from the exhaust filter were classified as bacteria of probable human origin, such as Streptococcus and Corynebacterium species. These were close to absent in intake dust samples (<1%). This suggests that occupancy shapes the indoor microbiota, creating an environment relatively rich in genera of potential health significance. There were significantly greater counts of culturable bacteria and fungi in exhaust samples, indicating that passage of air through the nursery causes deterioration in the general air quality. Although there was more endotoxin in exhaust dust, the endotoxin levels per colony forming unit were similar in both samples. This study explores, for the first time, the bacterial composition of ventilation filter dust in Norwegian nurseries, and is important as it reveals what types of microorganisms nursery users are exposed to. In addition to possible direct health issues, the nature of our early exposure to microbes may be significant in the development of immunological conditions.